Bausch&Lomb and Sanoculis announce strategic agreement designed to address unmet needs in Glaucoma

3 August, 2022

We are proud to have represented Bausch + Lomb in leading an equity investment in Sanoculis Ltd. as part of a Series C funding round of $14 million.

As part of this transaction, we also had the privilege of working alongside our terrific colleagues at Freshfields Bruckhaus Deringer in putting in place an options agreement, under which Bausch + Lomb obtained an option to purchase all of Sanoculis’ assets. Bausch & Lomb corporation is a leading global eye health company dedicated to helping people see better to live better.

Sanoculis Ltd. is a medical device start-up company that develops an innovative surgical procedure for the treatment of glaucoma.

The Bausch & Lomb corporation is a global eye health company that helps people see better to live better. Sanoculis Ltd. is a start-up medical device company which develops innovative glaucoma surgery procedures.

Bausch and Lomb were represented by attorneys Eliran Furman, Dana Kleiman and Intern Aharon Levenson.

Read full article >>

Want to know more?
Contact us

Shiri Menache

Head of Marketing and Business Development

Matan Bar-Nir

Press Officer, OH! PR